E-viri
PDF
Recenzirano
Odprti dostop
-
Cohen, Noah A.; Strong, Vivian E.; Janjigian, Yelena Y.
Journal of surgical oncology, July 1, 2018, Letnik: 118, Številka: 1Journal Article
There are few effective treatment options for metastatic esophagogastric adenocarcinomas after progression on second‐line chemotherapy. Immune checkpoint blockade therapy is a promising treatment strategy for selected advanced esophagogastric cancer, and the PD‐1 inhibitor pembrolizumab has recently been approved for metastatic or recurrent gastric or gastroesophageal junction cancer that has progressed beyond second‐line systemic therapy. We review the current data supporting immune checkpoint blockade therapy in advanced esophagogastric adenocarcinoma.
